Usage and monitoring of intravenous tobramycin in cystic fibrosis in Australia and the UK

Publisher： John Wiley & Sons Inc

E-ISSN： 2055-2335|46|1|15-21

ISSN： 1445-937x

Source： JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol.46, Iss.1, 2016-03, pp. : 15-21

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bayesian Optimisation of Tobramycin Dosing in Paediatric Patients with Cystic Fibrosis

By  

JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol. 41, Iss. 3, 2011-09 ,pp. : 183-187

John Wiley & Sons Inc

Access to resources Recommend Favorite

Inhaled tobramycin improves lung function and bacterial density associated with Pseudomonas aeruginosa infections in patients with cystic fibrosis

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 20, Iss. 9, 2004-09 ,pp. : 1-4

Adis International

Access to resources Recommend Favorite

Inhaled Tobramycin (TOBI®): A Review of its Use in the Management of Pseudomonas aeruginosa Infections in Patients with Cystic Fibrosis

By Cheer S.M.   Waugh J.   Noble S.  

Drugs, Vol. 63, Iss. 22, 2003-01 ,pp. : 2501-2520

Adis International

Access to resources Recommend Favorite

Drug Disposition in Cystic Fibrosis

By Rey E.   Tréluyer J-M.   Pons G.  

Clinical Pharmacokinetics, Vol. 35, Iss. 4, 1998-10 ,pp. : 313-329

Adis International

Access to resources Recommend Favorite

Nebulized Antibiotics in Cystic Fibrosis

By Sermetgaudelus I.  

Pediatric Drugs, Vol. 4, Iss. 7, 2002-01 ,pp. : 455-467

Adis International

Access to resources Recommend Favorite